NervGen Pharma Corp. Closes Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 892,721 units of the Company at a price of CA$2.60 per unit, for aggregate gross proceeds to the Company of CA$2,321,075. "We...
2021-11-29 9:16 AM EST
NervGen Pharma Reports Third Quarter 2021 Results
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the third quarter ended September 30, 2021. "Most notably, we made important progress in our Phase 1 clinical trial with NVG-291 in the third quarter of 2021," stated Paul...
2021-11-18 8:30 AM EST
NervGen Pharma Completes $9.2 Million Bought Deal Financing
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public offering (the "Offering") including the full exercise of the underwriters' over-allotment option. The Offering was made pursuant to an underwriting agreement entered into with...
2021-11-12 9:20 AM EST
NervGen Pharma Announces Increase to Bought Deal Financing to $8.0 Million
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce that, due to strong demand, the Company has agreed with a syndicate of underwriters led by iA Private Wealth Inc. and including Canaccord Genuity Corp. and Paradigm Capital Inc. (collectively, the "Underwriters"), to...
2021-11-05 9:52 AM EDT
NervGen Pharma Announces $5,000,000 Bought Deal Financing
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce that it has entered into an agreement with iA Private Wealth Inc. as lead underwriter and bookrunner, on behalf of a syndicate of underwriters including Canaccord Genuity Corp. and Paradigm Capital Inc. (collectively, the...
2021-11-04 4:04 PM EDT
NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided an update on its Phase 1 program with NVG-291 at the Society for Neuroscience's Neuroscience 2021 conference. NervGen's Chief Medical Officer, Dr. Daniel Mikol, presented blinded safety and pharmacokinetic data, including new data for...
2021-11-04 8:30 AM EDT
NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spinal Cord Injury (SCI) Clinical Advisory Board comprised of five world-class scientific and clinical researchers in the field of spinal cord injury: Drs. James Guest, Steven Kirshblum, Brian Kwon, Linda Jones...
2021-10-27 8:30 AM EDT
NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 14th Annual Meeting
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided a positive update on its Phase 1 program with NVG-291 in healthy volunteers at the 14th Annual Meeting of the American Neurological Association. NervGen's Chief Medical Officer, Dr. Daniel Mikol, presented interim blinded data from the...
2021-10-18 8:30 AM EDT
U.S. Senate Defense Bill Includes NervGen Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury
Cincinnati, Ohio--(Newsfile Corp. - October 4, 2021) - NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds the United States Senate Armed Services Committee for its release of the Fiscal Year 2022 National Defense Authorization Act (FY 22 NDAA) and the accompanying report language related to traumatic brain injury...
2021-10-04 8:30 AM EDT
NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a partnership with Imeka Solutions Inc. ("Imeka"), currently the only neuroimaging company that combines artificial intelligence and diffusion imaging to obtain high resolution images of white matter in the...
2021-09-27 8:30 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 550,000 incentive stock options to Directors exercisable at a price of $2.10 per share for a period of five years with vesting that is either time or performance based. All options...
2021-09-14 7:03 PM EDT
NervGen Pharma Presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021. The presentation will be available via webcast on demand starting on Monday, September 13, 2021,...
2021-09-12 4:45 PM EDT
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announces the results of its Annual General Meeting of Shareholders ("AGM") held on September 9, 2021. "We are very pleased to welcome Krista McKerracher and Glenn Ives to our Board of Directors as they are ideally suited...
2021-09-10 8:30 AM EDT
NervGen Pharma Provides an Operational Update on Its Ongoing Phase 1 Clinical Trial and Reports Second Quarter 2021 Results
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial results for the second quarter ended June 30, 2021. "The second quarter of 2021 was pivotal for NervGen as we started our Phase 1 clinical...
2021-08-19 8:30 AM EDT
NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer's Disease
Vancouver, British Columbia--(Newsfile Corp. - August 9, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen's lead compound, NVG-291, in validated animal models of Alzheimer's...
2021-08-09 8:30 AM EDT
NervGen Pharma Corp. Closes Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 1,511,636 units of the Company at a price of CAD$1.55 per unit, for aggregate gross proceeds to the Company of CAD$2,343,036. "I...
2021-08-05 8:30 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are...
2021-07-16 7:52 PM EDT
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the formation of its Multiple Sclerosis (MS) Clinical Advisory Board comprised of six world-class scientific and clinical researchers in the field of multiple sclerosis: Drs. Jack Antel, Peter Calabresi, Jeremy...
2021-07-15 8:30 AM EDT
NervGen Pharma Expands Alzheimer's Disease Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - July 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the addition of three world-class scientists and clinical researchers to its Alzheimer's Disease Scientific Advisory Board. Drs. Martin Farlow, Reisa Sperling and Michael Weiner have agreed to join Drs. Jeffrey...
2021-07-12 8:30 AM EDT
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced that it has engaged Vorticom Inc. ("Vorticom"), a New York based full-service public relations agency to provide media relations and related services for the Company. Vorticom was engaged for an initial term of two years on...
2021-06-25 5:00 PM EDT